Simvastatin
FDA-approved product (tablet, oral), marketed as Flolipid, Simvastatin, Zocor.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 2 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Abnormal circulating lipid concentration
- Acute myocardial infarction
- Cardiovascular disease
- Coronary artery disease
- Familial hypercholesterolemia
- Hypercholesterolemia
- Hyperlipidemia
- Myocardial infarction
- Stroke
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Hmg coa reductase inhibitors
- FDA pharmacologic class
- HMG-CoA Reductase Inhibitor FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA56.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli36.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae31.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis42.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Simvastatin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- DichlorphenamideExisting use: Glaucoma73.9% AI-predicted activityagainst M. tuberculosisLab records exist2 registered studies
- Tamsulosin HydrochlorideExisting use: Benign prostatic hyperplasia, Prostate carcinoma73.2% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Thiethylperazine MalateExisting use: Allergic disease71.8% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- SaquinavirExisting use: HIV infection, HIV-1 infection, Viral disease71.5% AI-predicted activityagainst M. tuberculosis50+ registered studies
- AvacopanExisting use: Anti-neutrophil antibody associated vasculitis, Anti-neutrophil cytoplasmic antibody-associated vasculitis, Granulomatosis with Polyangiitis and 1 more71.3% AI-predicted activityagainst M. tuberculosis26 registered studies
- Lasmiditan SuccinateExisting use: Migraine disorder71.0% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- SotorasibExisting use: Neoplasm, Non-small cell lung carcinoma71.0% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Vinblastine SulfateExisting use: Classic Hodgkin lymphoma, Fungal infectious disease, Hodgkins lymphoma and 3 more70.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Haloperidol DecanoateExisting use: Conduct disorder, Mental or behavioural disorder, Psychosis and 4 more70.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
- HydrochlorothiazideExisting use: Angina pectoris, Cardiovascular disease, Chronic kidney disease and 9 more70.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
- TolvaptanExisting use: Autosomal dominant polycystic kidney disease, Cardiovascular disease, Congestive heart failure and 4 more70.0% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Larotrectinib SulfateExisting use: Abdominal Neoplasms, Cancer, Metastasis and 1 more69.2% AI-predicted activityagainst M. tuberculosis5 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Effects of Statins on Pro- and Antioxidant Status : Link With Statin-Associated Myopathy.
NCT00285181 · start 2005-11
Registered record
- Registry ID
- NCT00285181
- Conditions
- Healthy
- Interventions
- Simvastatin
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2005-11
- Completion
- 2007-04
- Enrolment
- 24
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventionSimvastatinPhaseNot applicableRegistry statusCompletedBioequivalence Study of Simvastatin Tablets, 80 mg of Dr. Reddy's Under Fed Conditions
NCT01167933 · start 2005-01
Registered record
- Registry ID
- NCT01167933
- Conditions
- Healthy
- Interventions
- Simvastatin
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2005-01
- Completion
- 2005-04
- Enrolment
- 44
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventionSimvastatinPhasePhase 1Registry statusCompletedEffects on NF-κB Activity: High Dose Simvastatin Versus Combination Therapy With Ezetimibe
NCT01424891 · start 2004-04
Registered record
- Registry ID
- NCT01424891
- Conditions
- Type 2 Diabetes; Inflammation
- Interventions
- Simvastatin 80 mg; Sim10/Eze10; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2004-04
- Completion
- 2011-08
- Enrolment
- 31
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionType 2 Diabetes; InflammationInterventionSimvastatin 80 mg; Sim10/Eze10; PlaceboPhaseNot applicableRegistry statusCompletedCarotid Atherosclerosis Regression at Magnetic Resonance Assessment.
NCT00307307 · start 2000-01
Registered record
- Registry ID
- NCT00307307
- Conditions
- Established Carotid Atherosclerosis
- Interventions
- Niacin/simvastatin compared to simvastatin alone at 2 doses
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2000-01
- Completion
- 2005-09
- Enrolment
- 69
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionEstablished Carotid AtherosclerosisInterventionNiacin/simvastatin compared to simvastatin alone at 2 dosesPhasePhase 4Registry statusCompletedDrugs for High Blood Pressure and High Cholesterol in American Indians With Type 2 Diabetes
NCT00004266 · start 1993-08
Registered record
- Registry ID
- NCT00004266
- Conditions
- Diabetic Nephropathy
- Interventions
- Lisinopril; Nifedipine; Simvastatin
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 1993-08
- Completion
- 1999-07
- Enrolment
- 160
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDiabetic NephropathyInterventionLisinopril; Nifedipine; SimvastatinPhasePhase 3Registry statusCompleted